The export-side mirror of this repo's import/PLI-coverage bulletin: maps the 12 fastest-growing/highest-value HSN export chapters to their actual top destination countries via TRADESTAT, ranks countries by cross-sector exposure, and checks which PLI sub-schemes — Auto, Bulk Drugs, Textiles/MMF — actually support these chapters.
The USA takes 11 of India's 12 fastest-growing export chapters. That's a bigger concentration than China's grip on imports.
Cross-sector destination priority ranking
Combined FY2025-26 export value across the 12 growth chapters where each country appears as a top-8 destination.
The USA is the top-8 destination in 11 of the 12 fastest-growing export chapters, ranking #1 or #2 in 9 of them — $63.9bn combined across just these tracked chapters (India's total exports to the US were $87.31bn in FY2025-26 per IBEF/commerce data), more concentrated by both breadth and depth than China's grip on the import side (8 of 12 chapters, $102.4bn but spread across more evenly-ranked positions). UAE is the clear #2 destination (10 of 12 chapters, $26.9bn, #1/#2 in 6) — functioning as both a direct market and a regional re-export/refining hub. The next tier (Netherlands, China, Singapore, UK, Hong Kong, Germany) are each concentrated in 2-8 chapters at more modest shares.
The 12 growth export chapters: top destinations and PLI coverage
Ranked by FY2025-26 export value, same order as the source chart.
View all 12 sectors × top 8 destination countries
The rest of the PLI picture on the export side
PLI Auto & Auto Components (₹25,938 crore, FY2022-23 to FY2026-27, approved September 2021) targets Advanced Automotive Technology products — battery-electric and hydrogen fuel-cell vehicles specifically — and directly supports HS87 (vehicles, +43.5% since FY2018-19, USA/Mexico/South Africa/Saudi Arabia as top destinations). Budget 2026-27 nearly tripled its allocation to ₹5,939.87 crore from the FY2025-26 revised estimate of ₹2,091.26 crore. The complementary ACC Battery Storage PLI (₹18,100 crore, targeting 50 GWh capacity, 40 GWh already awarded) feeds the same EV value chain.
PLI Bulk Drugs (₹6,940 crore, FY2022-23 to FY2028-29) is the clearest cross-link between this bulletin and the companion import-side analysis: 48 projects selected, 34 commissioned across 25 to 26 APIs/KSMs/intermediates, ₹4,709 crore invested against a ₹3,938.5 crore commitment, generating ₹1,962 crore in sales (₹479 crore of it exports) and avoiding an estimated ₹1,483 crore in imports — explicitly aimed at cutting India's roughly 70% dependence on Chinese bulk-drug imports. It doesn't directly target HS30 (pharmaceutical formulations, +69.9% since FY2018-19, 34.6% to the USA) but supports it indirectly by reducing the HS29 (organic chemicals/API) import dependency that formulation exports rely on.
Iron & steel (HS72) and iron/steel articles (HS73) carry the same Specialty Steel PLI coverage (₹6,322 crore government outlay in rounds 1.0/1.1 — not the ₹44,106 crore private investment commitment the scheme has drawn from applicants, which this piece's earlier version conflated with it — plus ₹11,887 crore in round 1.2, MoUs signed February 2026) documented on the import side of this repo's analysis — one of the few schemes with genuinely matched coverage on both the import-substitution and export-growth sides of the same chapter.
- This is the export-side mirror of this repo's import/PLI-coverage bulletin — same method (TRADESTAT "commodity-wise, all countries," 2-digit HS, FY2025-26), applied to the 12 growth chapters from the export side of the HSN historical-trends bulletin rather than the import side.
- Netherlands, Singapore, UK and Hong Kong figures likely include re-export/entrepot flows whose final consumption market is elsewhere (Rotterdam is a major refined-petroleum and chemicals transshipment point for the whole EU; Singapore and Hong Kong play the same role regionally) — treat their rankings as directionally real trade-flow data, not necessarily final-market attribution.
- PLI incentives are calculated on incremental sales broadly, not export sales specifically, for most PLI schemes generally (this bulletin names Auto and Bulk Drugs specifically) — a company can earn the incentive from domestic sales growth alone. Bulk Drugs is the one scheme in this bulletin with an explicit, separately-tracked export figure.
- Country totals cross-check closely against this repo's own hsn_historical_trends chapter totals (e.g. HS27 $55,855.5M here vs $55,871.2M there; HS85 $53,999.8M vs $53,976.3M) — small differences reflect rounding and the exact retrieval timestamp, not a methodology change.
- Underlying data: data/export_destination_priority_and_pli_coverage_2026-07-18.json.
About this article: Researched, written and edited by Umashankar Triplicane Dwarakanathan, with AI research assistance; every figure is meant to trace to the primary source cited. See the Editorial Policy for how sourcing, AI use and corrections work.
